James Parker Brady, chief human resources officer at Ardelyx Inc., sold 15,136 shares of common stock on August 21, 2026, for a total of $58,378 under an automatic sell-to-cover arrangement tied to the vesting of restricted stock units.
The sale prices ranged from $3.648 to $3.984 per share, with a weighted average price of $3.8569. The transaction was executed solely to cover applicable withholding taxes, Brady’s attorney-in-fact, Felecia Ettenberg, confirmed in a Form 4 filing signed on August 25, 2026. Following the sale, Brady retains direct and beneficial ownership of 245,930 shares of Ardelyx common stock.
Ardelyx’s shares have declined sharply, down 42% over the past six months and near a 52-week low of $3.73. Trading volume in put options surged to 10,676 contracts, the highest since April 2025, indicating heightened bearish sentiment. The company reported a 31% year-over-year increase in second-quarter revenue to $118 million, its highest quarterly total on record. Ardelyx also updated its full-year guidance for IBSRELA and withdrew its revenue target for XPHOZAH, its two lead drug candidates.
